Data Insights
No filters selected
No filters selected
No filters selected
No filters selected
Ziftomenib by Kura Oncology for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia): Likelihood of Approval
Ziftomenib is under clinical development by Kura Oncology and currently in Phase II for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic...
Ziftomenib by Kura Oncology for Relapsed Acute Myeloid Leukemia: Likelihood of Approval
Ziftomenib is under clinical development by Kura Oncology and currently in Phase II for Relapsed Acute Myeloid Leukemia. According to...
Ziftomenib by Kura Oncology for Refractory Acute Myeloid Leukemia: Likelihood of Approval
Ziftomenib is under clinical development by Kura Oncology and currently in Phase II for Refractory Acute Myeloid Leukemia. According to...